Ionis Pharmaceuticals (FRA:ISI) Beta: -0.0780 (As of Jun. 26, 2026)


FRA:ISI Ionis Pharmaceuticals Inc FRA:ISI
65 GF Score
Price €67.38
GF Value €46.55
Valuation Significantly Overvalued
! 8 Warning Signs
View Full Analysis

What is Ionis Pharmaceuticals Beta?

Ionis Pharmaceuticals FRA:ISI +1.32% 65 Beta is -0.0780 as of Jun. 26, 2026. GuruFocus rates FRA:ISI with a GF Score™ of 65/100 and a GF Value™ of €46.55 (Significantly Overvalued). The stock has 8 warning signs investors should review.

Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. As of today (2026-06-26), Ionis Pharmaceuticals's Beta is -0.0780.


Ionis Pharmaceuticals  (FRA:ISI) Beta Explanation

Beta is a measure of the volatility, or systematic risk, of a security or a portfolio in comparison to the market as a whole. We usually compare beta to 1. A beta of 1 indicates that the security's price will move with the market. A beta of less than 1 means that the security will be less volatile than the market. A beta of greater than 1 indicates that the security's price will be more volatile than the market.

Beta is primarily used in the Capital Asset Pricing Model (CAPM) to calculate the Cost of Equity, which can be used in the calculation of WACC %. The formula of Cost of Equity is:
Cost of Equity = Risk-Free Rate of Return + Beta of Asset * (Expected Return of the Market - Risk-Free Rate of Return)


Ionis Pharmaceuticals Beta Related Terms


Ionis Pharmaceuticals Beta Historical Data

* Premium members only.

The historical data trend for Ionis Pharmaceuticals's Beta can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Ionis Pharmaceuticals Beta Chart

Ionis Pharmaceuticals Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Beta
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.75 0.44 -0.31 -0.11 0.67

Ionis Pharmaceuticals Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Beta Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.73 -0.83 -0.79 0.67 -0.40

FRA:ISI vs EXEL, BBIO, AXSM: Beta Comparison

For the Biotechnology subindustry, Ionis Pharmaceuticals's Beta, along with its competitors' market caps and Beta data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Ionis Pharmaceuticals Beta vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Ionis Pharmaceuticals's Beta distribution charts can be found below:

* The bar in red indicates where Ionis Pharmaceuticals's Beta falls into.


FRA:ISI
65GF Score
Ionis Pharmaceuticals Inc FRA:ISI
Beta is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Ionis Pharmaceuticals Beta Calculation

Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. A stock's beta can be calculated by dividing the product of the covariance of the individual stock's returns and the market's returns by the variance of the market's returns over a specified period. Basically, GuruFocus uses the returns calculated over three-year period.

Frequently Asked Questions Learn more about Beta →
What does a Beta of -0.0780 mean?
Ionis Pharmaceuticals (FRA:ISI) has a Beta of -0.0780 as of Jun. 26, 2026. Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. View historical data for Ionis Pharmaceuticals and its competitors.
Is Ionis Pharmaceuticals' Beta too high?
Ionis Pharmaceuticals' current Beta is -0.0780. Overall, Ionis Pharmaceuticals has a GF Score™ of 65/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Ionis Pharmaceuticals' Beta compare to EXEL and BBIO?
Ionis Pharmaceuticals' Beta of -0.0780 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beta for a Biotechnology company?
A good Beta depends on the Biotechnology industry context. However, Beta should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beta mean?
A high Beta can signal that a stock is expensive relative to its fundamentals. Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. View historical data for Ionis Pharmaceuticals and its competitors. Ionis Pharmaceuticals's current Beta is -0.0780. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ionis Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Ionis Pharmaceuticals (FRA:ISI) is currently considered Significantly Overvalued. The stock's GF Value™ is €46.55, compared to a current price of €67.38 — trading 44.7% above its estimated fair value. The current Beta is -0.0780. Ionis Pharmaceuticals' overall GF Score™ is 65/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beta calculated?
Beta is calculated from a company's financial statements. For Ionis Pharmaceuticals (FRA:ISI), the current Beta is -0.0780 as of Jun. 26, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Ionis Pharmaceuticals (FRA:ISI) Overvalued in 2026?

Based on GuruFocus' analysis, Ionis Pharmaceuticals stock appears to be overvalued. The current stock price of €67.38 is trading 44.7% above its estimated GF Value™ of €46.55. GuruFocus considers Ionis Pharmaceuticals to be Significantly Overvalued.

Key valuation signals for FRA:ISI:

  • Beta: -0.0780
  • GF Value™: €46.55 vs. price of €67.38 (44.7% above fair value)
  • GF Score™: 65/100 with 8 warning signs

No single metric tells the full story. See the FRA:ISI stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Ionis Pharmaceuticals Business Description

Other Exchanges IONS:USA1IONS:Italy0JDI:UK
Address 2855 Gazelle Court, Carlsbad, CA, USA, 92010
Ionis Pharmaceuticals is the leading developer of antisense technology to discover and develop novel drugs. Its broad clinical and preclinical pipeline targets a wide variety of diseases, with an emphasis on cardiovascular, metabolic, neurological, and rare diseases. Ionis and Biogen brought Spinraza to market in 2016 as a treatment for spinal muscular atrophy, and Biogen launched ALS drug Qalsody in 2023. Ionis brought two additional drugs to market via its cardiovascular-focused subsidiary Akcea, including ATTR amyloidosis drug Tegsedi (2018) and cardiology drug Waylivra (Europe, 2019). Ionis and AstraZeneca launched polyneuropathy drug Wainua in 2024. Ionis marked its first two independent launches in 2025 for Tryngolza (for FCS) and Dawnzera (for HAE).
65GF Score

Get the complete analysis for FRA:ISI

Beta is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€67.38
Price
€46.55
GF Value